loader
Our Twitter feed is currently unavailable but you can visit our official twitter page @avathemes.
  • Rhoncus montes. Tempor, ultrices. Platea eros, sociis odio! Vel diam dis? Scelerisque, ac etiam et dis mauris rhoncus cursus, pellentesque amet adipiscing porta montes massa enim porta augue? Proin, tincidunt, aliquam aliquet magna turpis.

    John Doe - McDonalds
  • Integer et augue augue nisi, phasellus ac massa a elementum sagittis, natoque, pulvinar auctor. Enim eu porttitor velit augue, scelerisque risus porttitor,

    JaneDoe - McDonalds
  • Rhoncus montes. Tempor, ultrices. Platea eros, sociis odio! Vel diam dis? Scelerisque, ac etiam et dis mauris rhoncus cursus, pellentesque amet adipiscing porta montes massa enim porta augue? Proin, tincidunt, aliquam aliquet magna turpis.

    BenDoe - McDonalds

About

R&D base Development of Bio-Macromolecules Synthesis Technology
Medical Devices manufacturing and sales

  • Development
    • ENGAIN’s own intelligent properties
    • Contains advanced-needs of academy
    • Be the leading player of advanced technology
    • Plan, Feasibility, Implementation, Verification, custom-fit & commercialization
    • Modification by customer’s need for better solution
    • Get the idea from market and improve it
    • Technological upgrade
  • Sales
    • A to Z of in-house manufacturing
    • Responsible for Patent works and Certification
    • Trusty delivery of goods
    • Business alliance with local Partner
    • Not the best partner, need suitable partner
    • Manufacturing & Delivery by ENGAIN, Buy & Distribution by Partner
    • Cooperation on local licensing (open the gateway of local market)
  1. Business

    • Non-Invasive C.G.M.S. by using Hydro-Gel
    • 1

      Technology:
      Hydro-Gel [Electrochemistry]
      Business:
      CGMS
      • We are The High-Tech. Medical Device Company based on Bio-Macromolecules Synthesis technology.
      • Our Strength is originated from Our novel core technology.

      Non-Invasive C.G.M.S. by using Hydro-Gel

      • You don’t need to do drawing blood many times per a day anymore.
      • This doesn’t ask you to collect your blood.
      • We measures your glucose from your interstitial fluid automatically and continuously.
      • The core competencies of Hydro-gel technologies are the extraction of interstitial fluid by reverse iontophoresis, the immobilization enzymes, and the electrochemical reaction between the enzymes and the substrates from extracted interstitial fluid.
      • Target is to achieve 10% market share out of USD 9 billion of world market.
      • [note] C.G.M.S. : Continuous glucose monitoring system
    • Embolic Agent by using Bio-Gel
    • 2

      Technology:
      Bio-Gel [Polymerchemistry]
      Business:
      Embolic Agent
      • We are The High-Tech. Medical Device Company based on Bio-Macromolecules Synthesis technology.
      • Our Strength is originated from Our novel core technology.

      Embolic Agent by using Bio-Gel

      • Among our core competent bio-macromolecular synthetic materials, Bio-gel having Nano-structure by the association with protein has been produced and the Bio-gel is primarily applicable to embolization for liver cancer patients.
      • Manufacturing and selling starts at 2Q 2015. Sales projection for 1’st year is USD 2.0 million and this is guaranteed by the contract with existing player.
      • Furthermore, the research project on the next generation Bio-gel associating with the contrasting agents is on-going in Engain Central Research Laboratories and the entrance of the next generation Bio-gel in the market is expected to replace conventional embolization agents by virtue of less use of contrasting agent.
      • We exclusively supply products to all major hospital locally in Korea and the transactions with overseas customer will be followed soon.
    • Non-Invasive C.G.M.S. by using Hydro-Gel
    • 3

      Technology:
      Nanofiber-Gel [Polymerchemistry]
      Business:
      Nano Filter
      • We are The High-Tech. Medical Device Company based on Bio-Macromolecules Synthesis technology.
      • Our Strength is originated from Our novel core technology.

      Hygro-Gel applied NanoFiber Filter

      • Our special hydro-gel technology is used in advanced nanofiber filter by electrospinning technology which is developed Japanese national university ShinShu.
      • This is named Hydro-gel based NanoFiber.
      • This electrospinning NanoFiber will be used as high performance filter, which is complexes web of ultrafine particles.
      • Firstly, this NanoFiber filter is applying to wearable mask materials to dustproof over 95% capture efficiency, which means significantly advanced performance of existing yellow
      • dust mask for PM 2.5 environment.
      • This NanoFiber mask launches 1Q 2015.
      • As a high performance membrane filter,
      • this NanoFiber filter is expecting highly expandable to various industry.
    • Non-Invasive C.G.M.S. by using Hydro-Gel
    • 4

      Technology:
      New Material-Gel [Nano-Bio]
      Business:
      Bio Signal Measurement
      • We are The High-Tech. Medical Device Company based on Bio-Macromolecules Synthesis technology.
      • Our Strength is originated from Our novel core technology.

      Body-signal measurement by using New material Gel

      • This is World first developing product and totally new technology.
      • Able to measure various body-signal such as glucose, PH, etc.
      • This will be situated as the true next generation glucose monitoring system soon.
      • Each development stage of this new material Gel will provide alternative solution against current technologies & products which are very old and expensive.
      • Proto-work is done and now preparing patents and papers.
      • Press release is planned within 2015, and following activities will come up such as clinical test and customization on products.

Mission

Improving people’s lives through meaningful innovation.

By tracking global trends and understanding the challenges facing people in their daily lives,we ensure that people’s needs and aspirations are at the heart of our innovation endeavors.

  • Creative for the future
  • Responsible
    for the customers
  • Entrepreneurial to win

News

2017년 1차 임시주주총회 소집공고

08.06.2017

2017년 1차 임시주주총회 소집공고   주주각위 주주님의 건승과 댁내의 평안을 기원합니다. 본 회사는 이사회 결의로 상법 제363조 및 당사 정관 제23조에 의거 ㈜엔게인 2017년 제1차 임시주주총회를 아래와 같이 소집하오니 참석하여 주시기 바랍니다.   – 아  래 – 1.일 시 : 2017년 6월 23일(금) / 오전 10시 2.장 소 : ㈜엔게인 본점 대회의실 (경기도 성남시 분당구 […]

Read More

신주발행 공고

08.06.2017

신주발행 공고 당사 이사회는 상법 제416조에 의거 2017년 6월 2일 아래와 같이 제3자배정 유상증자를 결의한바 동 의결사항을 상법 제418조 제4항에 따라 공고합니다.   1) 신주식의 종류와 수 : 상환전환우선주식 200,000주 2) 신주식의 액면금액: 1주 금 500원 3) 신주식의 발행가액: 1주 금 5,000원 4) 주금 납입기일 : 2017. 6. 30. 5) 주금 납입 금융기관: 기업은행 판교테크노밸리 […]

Read More

주주명부폐쇄기준일 공고

12.05.2017

주주명부폐쇄기준일 공고게시문 주주각위 < 주주명부폐쇄기준일 공고 > 상법 제354조 및 당사 정관 제16조의 규정에 의거 2017년 6월 22일 개최되는 임시주주총회에서 의결권을 행사할 주주를 확정하기 위하여 2017년 5월 29일부터 20 17년 6월 22일까지 주주명부를 폐쇄하오니 양지하시기 바랍니다. 20 17년  5월   12일 주식회사 엔게인 대표이사 고 영 국

Read More
contact us

ENGAIN Co., Ltd.
CEO : Young G. Koh

  • T. 031-628-0955
             F. 031-628-0957
  • main@engain.co.kr
  • Korea Bio Park BLD_C_2F
           Province of Gyunggi, Korea